Cargando…

Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient

Uric acid accumulates in renal failure and is thought to be a uremic toxin—that is, higher levels of uric acid are more damaging to the kidneys. Urate crystals can precipitate in the kidney tubules, cause urate stones, and promote inflammatory changes in the renal interstitium and vascular endotheli...

Descripción completa

Detalles Bibliográficos
Autores principales: Frassetto, Lynda Ann, Gibson, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856909/
https://www.ncbi.nlm.nih.gov/pubmed/27200198
http://dx.doi.org/10.1155/2016/9106935
_version_ 1782430560331759616
author Frassetto, Lynda Ann
Gibson, Suzanne
author_facet Frassetto, Lynda Ann
Gibson, Suzanne
author_sort Frassetto, Lynda Ann
collection PubMed
description Uric acid accumulates in renal failure and is thought to be a uremic toxin—that is, higher levels of uric acid are more damaging to the kidneys. Urate crystals can precipitate in the kidney tubules, cause urate stones, and promote inflammatory changes in the renal interstitium and vascular endothelium. Uric acid is also a small non-protein-bound molecule and therefore easily dialyzable. Here, we present the case of an anuric hemodialysis patient with severe tophaceous gout who regained some renal function and whose gout burden significantly decreased resulting in marked improvement in functional status using a new gout medication, febuxostat, and increased frequency of dialysis.
format Online
Article
Text
id pubmed-4856909
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-48569092016-05-19 Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient Frassetto, Lynda Ann Gibson, Suzanne Case Rep Nephrol Case Report Uric acid accumulates in renal failure and is thought to be a uremic toxin—that is, higher levels of uric acid are more damaging to the kidneys. Urate crystals can precipitate in the kidney tubules, cause urate stones, and promote inflammatory changes in the renal interstitium and vascular endothelium. Uric acid is also a small non-protein-bound molecule and therefore easily dialyzable. Here, we present the case of an anuric hemodialysis patient with severe tophaceous gout who regained some renal function and whose gout burden significantly decreased resulting in marked improvement in functional status using a new gout medication, febuxostat, and increased frequency of dialysis. Hindawi Publishing Corporation 2016 2016-04-21 /pmc/articles/PMC4856909/ /pubmed/27200198 http://dx.doi.org/10.1155/2016/9106935 Text en Copyright © 2016 L. A. Frassetto and S. Gibson. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Frassetto, Lynda Ann
Gibson, Suzanne
Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
title Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
title_full Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
title_fullStr Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
title_full_unstemmed Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
title_short Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
title_sort febuxostat and increased dialysis as a treatment for severe tophaceous gout in a hemodialysis patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856909/
https://www.ncbi.nlm.nih.gov/pubmed/27200198
http://dx.doi.org/10.1155/2016/9106935
work_keys_str_mv AT frassettolyndaann febuxostatandincreaseddialysisasatreatmentforseveretophaceousgoutinahemodialysispatient
AT gibsonsuzanne febuxostatandincreaseddialysisasatreatmentforseveretophaceousgoutinahemodialysispatient